Biocancell Therapeutics Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Clal Biotechnology Industries Ltd., was filed 07 Aug 2012.
Biocancell Therapeutics Inc.: what insiders have been doing
Biocancell Therapeutics Inc. is a listed company. Filings by its managers are published through SEC (Form 4). No insider at Biocancell Therapeutics Inc. has published a filing in the past twelve months. The most recent one dates from 7 August 2012.
Looking back to 2009, when coverage begins, insiders filed 4 purchases and no sales.
Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
- 4,147,171 shares@ US$0.217Common stockSEC:0001178913-12-002171:0
- 10,731,726 shares@ US$0.217Common stockSEC:0001178913-12-002171:1Canonical exit: 29 Oct 2012 (T+90)
- 8,199,400 shares@ US$0.26Common stockSEC:0001178913-12-000620:0Canonical exit: 23 Apr 2012 (T+90)
- 410,392 shares0Common stockSEC:0001178913-12-000620:1
- 800,463 sharesCommon Stock, par value $0.01SEC:0001178913-10-002258:0Canonical exit: 29 Oct 2008 (T+90)
- 7,143 sharesCommon Stock, par value $0.01SEC:0001178913-09-001608:0Canonical exit: 4 Oct 2009 (T+90)
6 of 6 declarations
About Biocancell Therapeutics Inc.
Biocancell Therapeutics Inc. is a company focused on developing innovative cancer treatments. It specializes in targeted therapies and personalized solutions to enhance patient outcomes.
